small molecule

GEREF

SERMORELIN ACETATE

Loss of exclusivity—loss of exclusivity

CompanyEMD Serono →See this company's full patent-cliff portfolio

Drug detail

Brand name	GEREF
Active ingredient	SERMORELIN ACETATE
Strength	EQ 0.05MG BASE/AMP Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons
Dosage form	INJECTABLE
Route	INJECTION
Modality	Small molecule
FDA approval	December 1990
Marketing status	DISCN

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.